Artificial intelligence is increasingly central to ensuring drug safety and optimizing biomanufacturing processes. Microsoft’s studies highlight AI’s dual-use potential in protein engineering, posing novel biosecurity risks. Industry experts emphasize the necessity of rigorous AI education to avoid misleading claims and maximize benefits in biomanufacturing. Companies like Meridian Bioscience balance roles as reagent suppliers and diagnostics developers, launching temperature-stable qPCR master mixes to improve workflow and reduce costs. These developments exemplify AI’s expanding influence in safe, efficient life sciences production.